Pharmacoeconomic analysis on six kinds of regimens using oral antidiabetic drugs in national essential medicines

JIANG Li-huan; CHEN Yue-chan; HUO Cai-feng

doi:10.3969/j.issn.1672-8157.2013.03.003

Abstract：Objective:To evaluate the pharmacoeconomic effect on the six kinds of regimens using oral antidiabetic drugs in national essential medicines for treating type 2 diabetes mellitus, and provide reference for drug choice. Methods:A total of 300 type 2 diabetic patients in outpatient of our hospital collected from March 2011 to August 2012 were assigned into 6 groups with 50 cases in each group. Metformin (group A), gliclazide sustained release tablets (group B), glimepiride (group C), metformin and glibenclamide (group D), metformin and glimepiride (group E) and metformin and gliclazide sustained release tablets (group F) were given in different groups, respectively. The treatment effect was observed 12 weeks later by evaluating fasting blood glucose, postprandial 2 h blood glucose and HbA1c. Pharmacoeconomic effect was compared by cost-effectiveness analysis. Results:Twelve weeks after the treatments, the costs of group A, B, C, D, E and F were 70.56 yuan, 198.24 yuan, 136.08 yuan, 42.84 yuan, 171.36 yuan and 233.52 yuan, respectively;and the total efficiencies were 86.0%, 88.0%, 88.0%, 84.0%, 94.0%and 92.0%, respectively. The value of C/E in group D was 51.00, which was the lowest;while value ofΔC/ΔE in group E was 12.85,ΔC/ΔE in group A was 13.86 by cost-effectiveness analysis. Conclusion:For the treatment of type 2 diabetes mellitus from our pharmacoeconomic analysis, group D (metformin and glibenclamide) was the most economical regimen, while group E (metformin and glimepiride) had the best efficacy, group A (metformin) was the best choice in monotherapy regimen, so reasonable choice of drugs in clinical treatment should be based on the specific situation of the patients.